Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

Chloe Orkin, Jean‐Michel Molina, Eugènia Negredo, José Ramón Arribas, Joseph Gathe, Joseph J. Eron, Erika Van Landuyt, Erkki Lathouwers, Veerle Hufkens, Romana Petrovic,

The Lancet HIV · 2017 · 96 citations · 19 references

Concepts

References

19